Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) announced that patient enrollment in its collaborative multiple sclerosis (MS) imaging study with Massachusetts General Hospital has reached the halfway mark. The study is evaluating a novel PET imaging technique using the [¹⁸F]3F4AP tracer to directly assess demyelination in the brain. Preliminary imaging data have shown encouraging signals in acute MS lesions and potential sensitivity to gray matter lesions, which could provide a more accurate way to measure disease activity and treatment response.
The company believes that this imaging technique could significantly enhance the development of MS therapies, including its own investigational candidate Lucid-MS. In March 2026, Quantum submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 2 trial of Lucid-MS. This candidate is designed to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, as demonstrated in preclinical models.
Multiple sclerosis affects approximately 2.8 million people worldwide, and current diagnostic tools often rely on indirect measures of demyelination. The ability to directly visualize demyelination using PET imaging could improve diagnosis, monitoring of disease progression, and evaluation of therapeutic efficacy. For patients, this could mean earlier and more precise treatment decisions. For the pharmaceutical industry, it could accelerate clinical trials by providing a more sensitive biomarker for drug effects.
Quantum BioPharma is a biopharmaceutical company focused on building a portfolio of innovative assets and biotech solutions for neurodegenerative, metabolic, and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is advancing Lucid-MS. Additionally, Quantum invented UNBUZZD™ and spun out its over-the-counter version to Unbuzzd Wellness Inc. Quantum retains a 19.84% ownership stake in Unbuzzd as of March 31, 2026, and is entitled to royalty payments of 7% of sales from unbuzzd™ until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations for pharmaceutical and medical uses.
The successful completion of the imaging study could provide Quantum with critical data to support the clinical development of Lucid-MS and potentially other therapies aimed at remyelination. It also underscores the company's commitment to leveraging advanced imaging technologies to address unmet needs in MS treatment. For investors, this milestone represents progress in the company's pipeline and may reduce the risk associated with drug development by providing more robust evidence of target engagement.
More information about Quantum BioPharma is available in the company’s newsroom at https://ibn.fm/QNTM.
